Skip to content
Companies

Paralos Bioscience

Phage-drug conjugates for drug-resistant infections

Raised to date

$647K

of $1M offered across 2 Form D filings

Still open
$353K
Investors
3
Last filed
Jun 23, 2026

About

Paralos Bioscience is a pre-clinical stage biotechnology company spun out of UCLA developing phage-drug conjugates for targeted delivery of antibiotics to drug-resistant bacteria. Its platform uses engineered M13 bacteriophage as a programmable carrier, combining high drug loading, targeting specific bacterial pathogens, and manufacturing by E. coli fermentation. The company is a member of the Magnify Incubator at UCLA's California NanoSystems Institute and is focused on drug-resistant Gram-negative infections that drive sepsis and pneumonia in hospital settings.

A modular phage conjugate system in which the targeting element and the drug payload can each be swapped independently, so one platform can be retargeted across pathogens and therapeutic payloads, while production runs on standard E. coli fermentation rather than a bespoke process.

Funding

  • EquityFiled Jun 23, 2026Form D/A
    $647K/ $1M
  • EquityFiled Apr 17, 2026Form D/A
    $329K/ $1M

Product

Phage-drug conjugate platform

Pre-clinical therapeutics platform

A bacteriophage-based conjugation technology built on engineered M13 phage that carries antibiotic payloads and delivers them specifically to targeted bacterial pathogens.

  • Engineered M13 bacteriophage carrier
  • High drug loading capacity per phage particle
  • Programmable targeting to specific bacterial pathogens

Built for

Hospitals and clinicians treating drug-resistant Gram-negative infections, and pharmaceutical partners in anti-infectives; the company cites the sepsis therapeutics market (~$3.95B in 2024) and the antibiotic resistance market (~$8.7B in 2023)

People on file